Belite Bio 配当と自社株買い
配当金 基準チェック /06
Belite Bio配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-1.9%
バイバック利回り
| 総株主利回り | -1.9% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
Seeking Alpha • Sep 09
Belite Bio On Track For A Potential Blockbuster Launch In 2027
Summary Belite Bio has stayed on track toward a potential blockbuster launch of tinlarebant in 2027, with FDA approval for STGD1 expected in February 2027. The FDA's acceptance of the NDA and priority review status reduce (but don't eliminate) regulatory risks, while label scope and pricing remain key unknowns. Management is planning to launch tinlarebant with a modest 50-rep sales force, but driving awareness among patients and general optometrists and ophthalmologists will be key over the long term. My base-case assumptions lead me to a fair value between $205 and $220, but a clean FDA approval with generous labeling and pricing meaningfully above $350K/year could drive significant upside. With $780M in cash and manageable burn, BLTE is a 'strong hold'—I would revisit it on a sentiment-driven pullback. Read the full article on Seeking Alpha
ナラティブ更新 • Sep 04
BLTE: Priority Review For Stargardt Therapy Will Shape Multi Blockbuster Potential
Belite Bio's analyst price target has moved higher from $211.50 to about $223.89 as analysts factor in recent target increases from several firms and renewed enthusiasm around tinlarebant following the FDA's acceptance of the NDA submission and long term U.S. sales potential modeled in recent research. Analyst Commentary Recent Street research on Belite Bio focuses heavily on the potential of tinlarebant, the valuation impact of higher long term sales assumptions and the execution risk around regulatory and commercial milestones in the U.S. Bullish Takeaways Bullish analysts highlight tinlarebant as a first therapeutic candidate to show a statistically significant reduction in lesion growth for Stargardt disease, which they see as a core driver for Belite Bio's long term revenue potential.
新しいナラティブ • Sep 04
Single-Drug Dependence And Delayed Trials Will Shape Future Retinal Therapy Prospects
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on therapies for retinal diseases such as Stargardt disease and geographic atrophy. What are the underlying business or industry changes driving this perspective?分析記事 • Jun 17
Belite Bio (BLTE) Stock Could Be 35% Undervalued After Tinlarebant NDA Submission
Why Belite Bio Stock Is Back in Focus After Tinlarebant NDA Milestone Belite Bio (BLTE) is drawing attention after completing its rolling New Drug Application submission to the FDA for tinlarebant, an oral therapy candidate for Stargardt disease type 1, a rare inherited retinal condition with no approved treatments. See our latest analysis for Belite Bio. Belite Bio’s latest regulatory milestone comes after a period where momentum has cooled in the share price, with the stock down 14.35% on a...新しいナラティブ • Mar 05
Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Oct 03
Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Belite Bio (NASDAQ:BLTE) is off 21% in Monday trading after reporting disappointing phase 2 results on tinlarebant for adolescent Stargardt Disease, a rare eye disease characterized by fatty material build-up in the macula. While the company presented the results in a positive light in a Friday evening news release -- a majority of the subjects showed stabilization of visual acuity in at least one eye and no atrophic lesion in 12 of 13 subjects over 12 months of treatment, investors seem less than impressed. Data also showed that fundus autofluorescence imaging indicated no autofluorescence expansion in 7 of 13 participants and 9 of 13 subjects demonstrated a stabilization or improvement in visual acuity. The trial is slated to last for two years.Seeking Alpha • Sep 16
Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Belite Bio (NASDAQ:BLTE) said on Friday it had received approval from the National Medical Products Administration of China to begin the Phase 3 trial of its drug, LBS-008, in adolescent with a rare type of eye disease called Stargardt disease STGD1. A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing. A Phase 3 trial, dubbed dragon, to Evaluate the Safety and Efficacy of LBS-008 in adolescent subjects had begun in the U.S., the United Kingdom, Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia, with several patients already enrolled.Seeking Alpha • Aug 22
Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Recently IPO’d Belite Bio, Inc (NASDAQ:BLTE) ended a four-day selloff on Monday to climb ~15% after the biopharma company announced the enrollments of its pivotal U.S. Phase 3 clinical trial for lead candidate LBS-008 in patients with eye disorder Stargardt Disease (STGD1). STGD1 has no FDA-approved therapies, and it is the commonest inherited retinal dystrophy that can lead to blurring and/or loss of central vision. LBS-008, an orally administered tablet, is currently undergoing a 2-year Phase 2 trial and a 2-year Phase 3 (DRAGON) trial involving adolescents with STGD1. The company plans to enroll about 60 subjects in the Phase 3 trial which is currently underway in the U.S., U.K., Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia. In Q4 2022, BLTE expects to launch a Phase 2/3 trial designed to evaluate the potential of LBS-008 in non-neovascular age-related macular degeneration (Dry AMD), another eye condition with no FDA-approved therapies. Read more about BLTE’s upcoming milestones.Seeking Alpha • Aug 12
Belite Bio GAAP EPS of -$0.23 beats by $0.05
Belite Bio press release (NASDAQ:BLTE): 1H GAAP EPS of -$0.23 beats by $0.05. As of June 30, 2022, the company had $48.7M in cash.Seeking Alpha • Jul 19
Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Belite Bio (NASDAQ:BLTE) on Tuesday said it had submitted an investigational new drug application to the U.S. FDA to proceed with its phase 3 trial of its oral tablet LBS-008 for the treatment of Stargardt disease (STGD1). STGD1 is a rare genetic eye disease that is characterized by fatty material build up on the macula. Belite Bio (BLTE) said it is currently conducting a 2-year phase 2 trial and a 2-year phase 3 trial of LBS-008 in adolescent STGD1 subjects. The company said its phase 3 trial, called DRAGON, had already been approved for enrollment in the UK, Switzerland, Hong Kong, Taiwan and Australia. U.S.-listed shares of BLTE earlier closed +5.3% at $43.70.決済の安定と成長
配当データの取得
安定した配当: BLTEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: BLTEの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| Belite Bio 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (BLTE) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.1% |
| 業界平均 (Pharmaceuticals) | 1.9% |
| アナリスト予想 (BLTE) (最長3年) | 0% |
注目すべき配当: BLTEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: BLTEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: BLTEの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: BLTEが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/10 14:07 |
| 終値 | 2026/09/10 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Belite Bio, Inc 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Steven Seedhouse | Cantor Fitzgerald & Co. |